logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 13 of 13 Items
Showing 1 - 13 of 13 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Editorial

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...
Journal Article
|
Review

Recent advances in the treatment of tuberculosis

Motta I, Boeree M, Chesov D, Dheda K, Günther G,  et al.
2023-07-21 • Clinical Microbiology and Infection
2023-07-21 • Clinical Microbiology and Infection
BACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...
Journal Article
|
Research

Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis

Hamada Y, Gupta RS, Quartagno M, Izzard A, Acuna-Villaorduna C,  et al.
2023-02-01 • eClinicalMedicine
2023-02-01 • eClinicalMedicine
BACKGROUND
Evidence on the comparative performance of purified protein derivative tuberculin skin tests (TST) and interferon-gamma release assays (IGRA) for predicting incident activ...
Journal Article
|
Review

Programmatic management of drug-resistant tuberculosis: an updated research agenda

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F,  et al.
2016-05-25 • PLOS One
2016-05-25 • PLOS One
INTRODUCTION
There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains li...
Journal Article
|
Research

Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis

Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A,  et al.
2020-03-20 • European Respiratory Journal
2020-03-20 • European Respiratory Journal
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...
Journal Article
|
Research

The Epidemiology, Pathogenesis, Transmission, Diagnosis, and Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R,  et al.
2017-03-15 • Lancet Respiratory Medicine
2017-03-15 • Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tube...
Journal Article
|
Research

Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis

Bisson GP, Bastos ML, Campbell JR, Bang D, Brust JCM,  et al.
2020-08-08 • Lancet
2020-08-08 • Lancet
BACKGROUND
HIV-infection is associated with increased mortality during multidrug-resistant tuberculosis treatment, but the extent to which the use of antiretroviral therapy (ART) and...
Journal Article
|
Research

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF,  et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Journal Article
|
Research

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J,  et al.
2012-08-28 • PLOS Medicine
2012-08-28 • PLOS Medicine
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the ...
Journal Article
|
Research

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A,  et al.
2020-03-17 • Lancet Respiratory Medicine
2020-03-17 • Lancet Respiratory Medicine

BACKGROUND

Tre...

Journal Article
|
Commentary

Clinical standards for the assessment, management and rehabilitation of post-TB lung disease

Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS,  et al.
2021-10-01 • International Journal of Tuberculosis and Lung Disease
2021-10-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the...